Explore a comprehensive toolkit featuring clinician- and patient-friendly resources including implementation guides, patient education on BCMA-directed bispecific antibodies, podcasts, and more to support the use of bispecific antibody treatment in your practice.
Bispecific antibodies are transforming the treatment landscape of multiple myeloma. For patients with RRMM who start treatment with a bispecific antibody at a tertiary center but prefer to receive ongoing care closer to home, the question becomes: how does a community cancer center ensure continuity of care for this patient? Listen to Sara Scott, PharmD, BCOP, and Jaime Román, MPAS, PA-C, as they discuss implementing bispecific antibodies in community oncology clinics.
The decision to choose a bispecific antibody for multiple myeloma treatment is complex, and providers need to consider both patient- and disease-specific factors. Join Camille Edwards, MD, and Theresa, a patient with multiple myeloma, as they discuss Theresa’s experience with bispecific antibody treatment and the importance of patient-provider communication, including during the care transition from specialty centers to community-based settings.
Dr. Nooka discusses how he manages patients who live far from an academic center and highlights the importance of having SOPs in place to help with transitioning patients back to the community.
Dr. Nooka discusses the management of toxicities including CRS and ICANS, the prophylactic use of tocilizumab, and the prevention of infectious complications.
Drs. Nooka and Szalat discuss the administration schedule for bispecific antibodies and how to handle missed doses.
Drs. Nooka and Szalat discuss the importance of continual communication between the academic and community centers to ensure that patients receive optimal care.
Explore resources that you can use in your practice, including information on how to implement bispecific antibody treatment in your practice.
Access resources that you can share with your patients, including a guide to bispecific antibodies and information about the various BCMA-directed bispecific antibody options for multiple myeloma.